Evidence map›Paper›PMID 25623948›Full record

ArticleMolecular psychiatry2015

Dysregulation of miR-34a links neuronal development to genetic risk factors for bipolar disorder.

S Bavamian, N Mellios, J Lalonde, D M Fass, J Wang, S D Sheridan, J M Madison, Fen Zhou, E H Rueckert, D Barker and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 165 citations in OpenAlex.

  1. Mental health dished up-the use of iPSC models in neuropsychiatric research.Journal of neural transmission (Vienna, Austria : 1996) · 2020
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  6. Plasma miRNA Profiles in Chronically Treated Bipolar Disorder Patients: A Case-Control Study.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. RNA Biomarkers in Bipolar Disorder and Response to Mood Stabilizers.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Review

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

S Bavamian1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
N MelliosDepartment of Brain and Cognitive Sciences, Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
J Lalonde1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000000267971894
D M Fass1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
J Wang1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [4] Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
S D Sheridan1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [4] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [5] Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
J M Madison1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Fen Zhou1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
E H Rueckert1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
D BarkerStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
R H Perlis1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [4] Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
M SurDepartment of Brain and Cognitive Sciences, Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.
S J Haggarty1] Chemical Neurobiology Laboratory, Center for Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA [2] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA [3] Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [4] Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [5] Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Broad Institute · USMassachusetts General Hospital · USMassachusetts Institute of Technology · US

Funding

Chemical Genomic Approaches to Neurobiology of DISC1R01MH091115 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TSAI, LI-HUEI · 2010 to 2014
$3.4M
Functional Genomics of Neuroplasticity in SchizophreniaR01MH095088 · NIMH · BROAD INSTITUTE, INC. · PI HAGGARTY, STEPHEN J · 2011 to 2014
$2.5M
Genomics-Guided Characterization of iPS Cells from Common Mental IllnessesR33MH087896 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HAGGARTY, STEPHEN J · 2011 to 2012
$872k
In vitro and in vivo study of simvastatin plus lithium in bipolar depressionR21MH093958 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HAGGARTY, STEPHEN J, PERLIS, ROY H. · 2012 to 2013
$674k
Genomics-Guided Characterization of iPS Cells from Common Mental IllnessesR21MH087896 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HAGGARTY, STEPHEN J · 2009 to 2010
$525k
NIMH NIH HHS R01 MH091115NIMH NIH HHS R01MH091115NIMH NIH HHS R01 MH095088NIMH NIH HHS R01MH095088NIMH NIH HHS R21 MH087896NIMH NIH HHS R21 MH093958NIMH NIH HHS R21MH093958NIMH NIH HHS R33 MH087896NIMH NIH HHS R33MH087896
6 · The paper itself

Abstract

Bipolar disorder (BD) is a heritable neuropsychiatric disorder with largely unknown pathogenesis. Given their prominent role in brain function and disease, we hypothesized that microRNAs (miRNAs) might be of importance for BD. Here we show that levels of miR-34a, which is predicted to target multiple genes implicated as genetic risk factors for BD, are increased in postmortem cerebellar tissue from BD patients, as well as in BD patient-derived neuronal cultures generated by reprogramming of human fibroblasts into induced neurons or into induced pluripotent stem cells (iPSCs) subsequently differentiated into neurons. Of the predicted miR-34a targets, we validated the BD risk genes ankyrin-3 (ANK3) and voltage-dependent L-type calcium channel subunit beta-3 (CACNB3) as direct miR-34a targets. Using human iPSC-derived neuronal progenitor cells, we further show that enhancement of miR-34a expression impairs neuronal differentiation, expression of synaptic proteins and neuronal morphology, whereas reducing endogenous miR-34a expression enhances dendritic elaboration. Taken together, we propose that miR-34a serves as a critical link between multiple etiological factors for BD and its pathogenesis through the regulation of a molecular network essential for neuronal development and synaptogenesis.

Indexed as

AdolescentAdultAnkyrinsBipolar DisorderBrainCalcium ChannelsCell DifferentiationCells, CulturedFemaleGene Expression RegulationHumansInduced Pluripotent Stem CellsMaleMicroRNAsMiddle AgedNerve Tissue ProteinsANK3 protein, humanAnkyrinsCACNB3 protein, humanCalcium ChannelsMicroRNAsMIRN34 microRNA, humanNerve Tissue ProteinsTranscription Factors

Identifiers

PMID25623948
PMCPMC4414679
OpenAlexW2078953727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.